Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
Perspective Therapeutics (NYSEAMERICAN:CATX) presented updated clinical data for its VMT-α-NET program at the European Society for Medical Oncology Congress 2026, reporting tumor responses, an 18-month progression-free survival landmark rate of 72% across three cohorts and no dose-limiting toxicities in the study to date. The company is developing VMT-α-NET for somatostatin receptor 2-positive gastroenteropancreatic neuroendocrine tumors, […]
24 Oct 23:03 · The Markets Daily